Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Page 1
Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
Lancet Infect Dis. 2015 Dec;15(12):1398-408. doi: 10.1016/S1473-3099(15)00247-9. Epub 2015 Nov 4.
Lancet Infect Dis. 2015.
PMID: 26511956
Clinical Trial.
We aimed to assess the safety and efficacy of an anti-RSV monoclonal antibody (motavizumab) in healthy term (36 weeks' gestational age) infants for the prevention of medically attended RSV acute lower respiratory tract infections. ...The findings do not support a direct, g …
We aimed to assess the safety and efficacy of an anti-RSV monoclonal antibody (motavizumab) in healthy term (36 weeks' gestational ag …
Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
Ramilo O, Lagos R, Sáez-Llorens X, Suzich J, Wang CK, Jensen KM, Harris BS, Losonsky GA, Griffin MP; Motavizumab Study Group.
Ramilo O, et al. Among authors: losonsky ga.
Pediatr Infect Dis J. 2014 Jul;33(7):703-9. doi: 10.1097/INF.0000000000000240.
Pediatr Infect Dis J. 2014.
PMID: 24356256
Clinical Trial.
BACKGROUND: This study was conducted to determine whether treatment with motavizumab, an anti-respiratory syncytial virus (RSV) monoclonal antibody, would decrease viral load and improve clinical outcomes in previously healthy term infants hospitalized with RSV lower respi …
BACKGROUND: This study was conducted to determine whether treatment with motavizumab, an anti-respiratory syncytial virus (RSV) monoclonal a …
Item in Clipboard
Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization.
Losonsky GA, Wasserman SS, Stephens I, Mahoney F, Armstrong P, Gumpper K, Dulkerian S, West DJ, Gewolb IH.
Losonsky GA, et al.
Pediatrics. 1999 Feb;103(2):E14. doi: 10.1542/peds.103.2.e14.
Pediatrics. 1999.
PMID: 9925860
The seroprotection rate (attaining >/=10 mIU/mL HBS antibody) after two doses was low (25%) regardless of birth weight; infants weighing <1000 g at birth had the poorest response (11%). The seroprotection response rate after three doses of vaccine increased wi …
The seroprotection rate (attaining >/=10 mIU/mL HBS antibody) after two doses was low (25%) regardless of birth weight; infants we …
Item in Clipboard
Cite
Cite